The New York Stock Exchange is making a bid to lure biotechnology IPOs that usually go to Nasdaq, the latest sign of an intensifying rivalry between the two exchanges.

NYSE is lowering fees for companies with little to no revenue, a typical characteristic of biotechnology firms still in the development phase. Biotechs historically have mostly listed on Nasdaq, in part because of its cheaper fees, more lenient listing standards and the prospect of inclusion in the popular Nasdaq Biotechnology Index.